Two recently-published studies of LifeScan‘s OneTouch Verio Flex blood glucose monitoring system showed that the technology is accurate, reliable and linked with improvements in glycemic control, the Johnson & Johnson (NYSE:JNJ) business touted today.
The release comes just days after the healthcare giant revealed that it plans to shut down its Animas insulin pump business and review its LifeScan division.
In a LifeScan-funded study published in the Journal of Diabetes Science and Technology, researchers tested three lots of the OneTouch Verio Flex blood glucose monitoring system and reported that the technology met and exceeded the minimum requirements of the ISO standard for system accuracy.
A different study, conducted by LifeScan and published in the August issue of JMIR Diabetes, enrolled 128 adults with sub-optimally controlled Type I and II diabetes and assigned them into two groups – one group that switched from their current blood glucose monitoring system to the OneTouch Verio Flex and another group that switched from their current system to the OneTouch Verio Flex paired with the OneTouch Reveal mobile app.
The company reported that the study’s results showed improved glycemic control at 12 and 24 weeks in both the meter-only and meter-plus-mobile-app groups compared to baseline.
“Self-monitoring of blood glucose is still the most accurate, effective and accessible way people with diabetes can track their blood sugars,” LifeScan’s CMO Dr. Brian Levy said in prepared remarks.
“With the OneTouch Verio Flex blood glucose monitoring system, we are proud to offer people with diabetes and their care teams a very accurate system that they know they can trust. Building on that accuracy, we now have our interconnected diabetes management OneTouch Reveal system that changes the way patients see their blood sugar. This enables both patients and physicians to use that information to make meaningful decisions about their diabetes management.”
LifeScan also touted its OneTouch Reveal mobile app as the most-downloaded diabetes app in the U.S., Canada, France and the U.K., with 420,000 total downloads.
